JP2024507414A - ウイルス感染症治療のためのｒｏｃｋ２阻害剤 - Google Patents

ウイルス感染症治療のためのｒｏｃｋ２阻害剤 Download PDF

Info

Publication number
JP2024507414A
JP2024507414A JP2023575684A JP2023575684A JP2024507414A JP 2024507414 A JP2024507414 A JP 2024507414A JP 2023575684 A JP2023575684 A JP 2023575684A JP 2023575684 A JP2023575684 A JP 2023575684A JP 2024507414 A JP2024507414 A JP 2024507414A
Authority
JP
Japan
Prior art keywords
ring
membered
group
alkyl
saturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507414A5 (https=
Inventor
ディー．ワクサル サミュエル
ウー ルイ
Original Assignee
グラビトン バイオサイエンス べスローテン フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラビトン バイオサイエンス べスローテン フェンノートシャップ filed Critical グラビトン バイオサイエンス べスローテン フェンノートシャップ
Publication of JP2024507414A publication Critical patent/JP2024507414A/ja
Publication of JP2024507414A5 publication Critical patent/JP2024507414A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023575684A 2021-02-22 2022-02-22 ウイルス感染症治療のためのｒｏｃｋ２阻害剤 Pending JP2024507414A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163152260P 2021-02-22 2021-02-22
US63/152,260 2021-02-22
PCT/US2022/017312 WO2022178420A1 (en) 2021-02-22 2022-02-22 Rock2 inhibitor for the treatment of viral infection

Publications (2)

Publication Number Publication Date
JP2024507414A true JP2024507414A (ja) 2024-02-19
JP2024507414A5 JP2024507414A5 (https=) 2025-02-26

Family

ID=82931820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575684A Pending JP2024507414A (ja) 2021-02-22 2022-02-22 ウイルス感染症治療のためのｒｏｃｋ２阻害剤

Country Status (8)

Country Link
US (1) US20240165116A1 (https=)
EP (1) EP4301132A4 (https=)
JP (1) JP2024507414A (https=)
KR (1) KR20240009918A (https=)
CN (1) CN117529320A (https=)
AU (1) AU2022224669A1 (https=)
CA (1) CA3209240A1 (https=)
WO (1) WO2022178420A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202327608A (zh) * 2021-09-17 2023-07-16 北京泰德製藥股份有限公司 治療病毒感染的方法
EP4393917A4 (en) * 2021-09-18 2025-09-10 Beijing Tide Pharmaceutical Co Ltd SOLID FORM OF A RHO-ASSOCIATED PROTEIN KINASE INHIBITOR OR SOLVATE THEREOF, METHOD OF PREPARATION AND USE THEREOF
CN121368592A (zh) * 2023-04-18 2026-01-20 盖诺斯克公司 Rock2蛋白激酶的血脑屏障穿透性选择性抑制剂及其用途
AU2024256326A1 (en) * 2023-04-18 2025-11-27 Genosco Inc. Selective inhibitors of rock2 protein kinases and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020525522A (ja) * 2017-06-30 2020-08-27 ベイジン タイド ファーマシューティカル カンパニー リミテッドＢｅｉｊｉｎｇ Ｔｉｄｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Ｒｈｏ−関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470137A (en) * 1967-02-14 1969-09-30 Du Pont Inter se copolymers of bicyclo(1.1.0)butanes
JP6593305B2 (ja) * 2016-11-09 2019-10-23 株式会社村田製作所 二次電池用電解液、二次電池、電池パック、電動車両、電力貯蔵システム、電動工具および電子機器
EP3992183A4 (en) * 2019-06-25 2023-06-21 Beijing Tide Pharmaceutical Co., Ltd. METHODS OF TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
KR20230061444A (ko) * 2020-08-31 2023-05-08 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Rho-연관 단백질 인산화효소 억제제의 염, 염의 고체 형태, 이의 제조 방법 및 이의 용도
EP4393917A4 (en) * 2021-09-18 2025-09-10 Beijing Tide Pharmaceutical Co Ltd SOLID FORM OF A RHO-ASSOCIATED PROTEIN KINASE INHIBITOR OR SOLVATE THEREOF, METHOD OF PREPARATION AND USE THEREOF
CN118215468A (zh) * 2021-11-16 2024-06-18 北京泰德制药股份有限公司 一种rock2抑制剂的纳米晶制剂及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020525522A (ja) * 2017-06-30 2020-08-27 ベイジン タイド ファーマシューティカル カンパニー リミテッドＢｅｉｊｉｎｇ Ｔｉｄｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Ｒｈｏ−関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用

Also Published As

Publication number Publication date
CA3209240A1 (en) 2022-08-25
EP4301132A1 (en) 2024-01-10
EP4301132A4 (en) 2025-03-26
KR20240009918A (ko) 2024-01-23
WO2022178420A1 (en) 2022-08-25
AU2022224669A1 (en) 2023-09-28
CN117529320A (zh) 2024-02-06
US20240165116A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
JP2024507414A (ja) ウイルス感染症治療のためのｒｏｃｋ２阻害剤
CN101990434B (zh) 用于治疗沙粒病毒感染的抗病毒药物
EP3437644B1 (en) Compounds for use in the treatment of pulmonary hypertension
WO2020016427A1 (en) Inhibitors of hepatitis b virus
US20190070212A1 (en) Compounds and compositions for the treatment of infections
EP3395344B1 (en) Medicine for treating heart failure
PT99434A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de xantina
US20240041861A1 (en) Compositions and methods for treatment and prophylaxis of viral infections
CZ2001977A3 (cs) Kombinace účinných látek
US20260007673A1 (en) Rock2 inhibitors for the treatment of viral infections
JP2014532636A (ja) ウイルス感染の処置のためのヌクレオシドアナログおよび該処置に対する感受性を評価するための方法
WO2001030329A2 (en) Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction
KR20010075202A (ko) 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제
HK40000144B (en) Compounds for use in the treatment of pulmonary hypertension
JPH0551567B2 (https=)
HK1262939B (en) Medicine for treating heart failure
HK40000144A (en) Medicine
HK1262939A1 (en) Medicine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310